Oppenheimer调整Satellos Bioscience目标价至$40 反映1:12合股影响

美股速递
Feb 10

投资机构Oppenheimer宣布更新对生物科技公司Satellos Bioscience Inc.的目标股价评估。此次调整将目标价从原先的5美元大幅上调至40美元,主要原因是该公司近期实施了1股合并为12股的反向股票分割操作。

这一价格变动纯粹反映合股后的股本结构变化,并不代表投资机构对该公司基本面或估值观点的实质性改变。反向拆股通常被上市公司用于提升每股交易价格,以满足交易所的上市维持标准或改善市场流动性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10